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Background: TLR9 agonists are being developed as immunotherapy against malignancies and infections. TLR9 is
primarily expressed in B cells and plasmacytoid dendritic cells (pDCs). TLR9 signalling may be critically impor-
tant for B cell activity in lymph nodes but little is known about the in vivo impact of TLR9 agonism on human
lymph node B cells. As a pre-defined sub-study within our clinical trial investigating TLR9 agonist MGN1703
(lefitolimod) treatment in the context of developing HIV cure strategies (NCT02443935), we assessed TLR9
agonist-mediated effects in lymph nodes.
Methods: Participants receivedMGN1703 for 24weeks concurrentwith antiretroviral therapy. Sevenparticipants
completed the sub-study including lymphnode resection at baseline and after 24weeks of treatment. A variety of
tissue-based immunologic and virologic parameters were assessed.
Findings:MGN1703 dosing increased B cell differentiation; activated pDCs, NK cells, and T cells; and induced a
robust interferon response in lymph nodes. Expression of Activation-Induced cytidine Deaminase, an essential
regulator of B cell diversification and somatic hypermutation, was highly elevated. During MGN1703 treatment
IgG production increased and antibody glycosylation patterns were changed.
Interpretation:Our data present novel evidence that the TLR9 agonistMGN1703modulates human lymph node B
cells in vivo. These findingswarrant further considerations in the development of TLR9 agonists as immunother-
apy against cancers and infectious diseases.
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1. Introduction
Pattern recognition receptors are innate molecules that sense
pathogen-associated or danger-associated molecular patterns [1]. One
such receptor, the toll-like receptor 9 (TLR9), is found primarily in
endosomes of plasmacytoid dendritic cells (pDCs) and B cells where it
detects non-methylated cytosine-guanine (CpG) DNA motifs [2,3].
These dinucleotide motifs are frequently found in bacterial DNA as
well as in transformed cells [1–4]. The downstream effects of TLR9
stimulation in human pDCs are well described ex vivo and in vivo
[1–8]. In short, TLR9 stimulated pDCs produce interferon α (IFN-α).
This type I interferon production leads to a stimulatory environment
that results in T, NKT, and NK cells becoming activated with improved
capacity for cytotoxic effector functions. Since engaging TLR9 leads to
heightened activity of immune effector cells, the development of TLR9
agonists as immunotherapy for cancers and infectious diseases is a
field of intense research.
TLR9 agonists include multiple classes of CpG DNA oligonucleo-
tides (CpG ODNs) as well as members of the double stem loop immu-
nomodulator (dSLIM) class of molecules [2,4]. CpG ODNs are linear
DNA fragments that harbor CpG motifs and these fragments are typ-
ically protected from nuclease degradation by a modified phospho-
rothioate backbone. To avoid chemical modification leading to
unwanted side effects, the dSLIM molecules utilize a covalently-
closed dumbbell-shaped configuration offering protection from
nucleases. Because the major effects of TLR9 stimulation occur in
lymphoid tissue, we need to study this specific anatomical compart-
ment to fully understand how TLR9 agonists engage the immune sys-
tem. Such investigations provide profound insights into how
responses to TLR9 agonism differ between anatomical compart-
ments. For example, we previously reported compartmentalized
human intestinal responses to MGN1703 (lefitolimod; a member of
the dSLIM class of TLR9 agonists [4,9–11]) dosing that were quite nu-
anced and limited to a type I interferon response [6]. This was dis-
tinct from findings in peripheral blood, which revealed that these
same individuals mounted both type I and type II interferon re-
sponses [6]. In comparison to the immune effector functions that
occur in intestines, lymph nodes function primarily as inductive
sites for adaptive immune responses. Improved antibody maturation
and function are key among the essential adaptive immune re-
sponses that are manifested in lymph node follicles [12]. B cell folli-
cles can be found either as primary follicles or secondary follicles.
When an antigen stimulates a B cell, the B cell acquire the ability to
migrate into primary follicles, where the B cells receive signals
from follicular dendritic cells and T follicular helper cells to prolifer-
ate and form a germinal center. This formation of a germinal center
creates a secondary follicle. In the secondary follicle the B cells
undergo somatic hypermutation, affinity maturation and selection
for differentiation into memory B cells or plasma cells [12,13].
B cells and plasma cells express TLR9 [14], however, knowledge on
how TLR9 signalling affects human peripheral B cells is incomplete
and the impact of TLR9 agonist treatment on human lymph node B
cells is unknown. Ex vivo and in vivo murine studies as well as ex vivo
humanB cell studies have shown that TLR9 agonismpromotes B cell dif-
ferentiation and proliferation, which is accompanied by immunoglobu-
lin class switching and antibody production [15–21]. Interestingly, in
small-cell lung cancer patients presence of activated B cells have
shown a predictive value for overall survival in a small patient popula-
tion, which points to the importance of a further evaluation of B cell
populations [10]. Thus, it remains an open question how TLR9 agonism
impacts human B cell differentiation and function in vivo [22]. Further-
more, it is unknown whether peripheral blood outcomes of TLR9 stim-
ulation mirror the impacts of TLR9 agonist treatment in lymph nodes.
To answer these important questions, we examined lymph nodes
alongside with paired peripheral blood samples at baseline and during
MGN1703 administration in a clinical trial among HIV patients.
Research in context
Evidence before this study
Synthetic TLR9 agonists are being developed as immunotherapy
for the treatment of cancers and chronic infections aswell as vac-
cine adjuvants. Fewhuman PBMC in vitro ormurine in vivo studies
have examined the direct effect of TLR9 agonists on B cells. Al-
though the analyses utilized in these studies were not designed
for in depth interrogation of B cells, they indicated that B cell pro-
liferation and differentiation are stimulated by TLR9 agonism.
However, no previous studies have investigated the in vivo TLR9
agonist impact on B cells in human lymph nodes. A trio of papers
reported that local application of a TLR9 agonist at the site of mel-
anoma resection was sufficient to induce dendritic cell and cyto-
toxic T cell activation in sentinel lymph nodes. Collectively, the
literature on TLR9 agonist impact on human B cells differentiation
and function is very limited.
Added value of this study
Here we present an unprecedented longitudinal study of lymph
node biology across 24weeks of TLR9 agonist therapy in humans.
We also provide novel evidence that TLR9 agonist treatment read-
ilymodulates human B cell population dynamics in vivo. The study
population consists of HIV-infected individuals who continued
suppressive standard-of-care antiretroviral therapy throughout
the duration of TLR9 agonist treatment. Thus, we do not only
offer novel insights into basic lymph node biology during TLR9 ag-
onist treatment, but we also present data on HIV persistence in
lymph nodes from a large cohort of paired lymph node samples.
Implications of all the available evidence
Our data demonstrates that TLR9 agonism promotes B cell differ-
entiation and leads to increased levels of antibodies, which exhibit
altered glycosylation patterns. Specific TLR9 agonist-modulated
glycosylation changes were associated with reductions in the
amount of HIV that persists during standard-of-care antiretroviral
therapy. The new knowledge presented here has immediate
value for the design and conduct of interventional trials utilizing
TLR9 agonist immunotherapy for oncology and infectious
diseases.
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2. Materials and methods
2.1. Study design and participants
Fourteen HIV-1 infected individuals on long-term cART were en-
rolled in the TEACH-B study (Toll-like receptor 9 enhancement of anti-
viral immunity in chronic HIV-1 infection part B: an investigator
initiated single-arm, phase Ib/IIa clinical trial; ClinicalTrials.gov ID:
NCT02443935) [8]. Twelve participants completed the study. The
study was approved by the National Health Ethics Committee,
Denmark (#1–10–72-10-15) and the Danish Medical and Health Au-
thorities (#2015014125). Each participant provided written informed
consent before any study activities. During the interventional phase of
TEACH-B, participants continued to take cART as they received two bi-
lateral subcutaneous injections of 60 mg MGN1703 [lefitolimod;
Mologen AG, Berlin, Germany] two times per week for 24 weeks
(Fig. 1a). MGN1703 injections were either in each side of the abdomen
or in each upper thigh.
2.2. Lymph node harvest and processing
Of the fourteen individuals eight participants consented to have a
lymph node excision at baseline and during the last week of treatment
(week 24) (Fig. 1a). Upon ultrasonic verification of the lymph node lo-
calized laterally to the superficial circumflex iliac artery, the lymph
node was marked on the skin. Lymph nodes from baseline and during
week 24 were taken from either side. The lymph node was excised
using ultrasonography guided electrocautery. Immediately after exci-
sion, ~20% of the lymph node was placed in 10% NBF for 24 h and then
paraffin embedded. Non-fixed lymph node tissues were stored on ice
in “suspension media” (i.e. PBS supplemented with 0·5% BSA, 1% Pen/
Strep and excess DNase) for transport. Once in the laboratory, lymph
node tissues were immediately processed to isolate lymph nodemono-
nuclear cells (LNMC). LNMC were extracted via mechanical disruption,
washed in suspensionmedia and strained through a 70 μmcell strainer.
The lymph node wash supernatant was saved and stored at -80 °C for
antibody glycosylation analysis. LNMC were analysed fresh by flow cy-
Fig. 1.MGN1703 treatment activates lymphnodeplasmacytoid dendritic, natural killer cells andT cells. (a) Study outline ofMGN1703dosing and sample collection time points. During the
intervention the study participants continued cART treatment. (b-c) Proportions of lymph node pDC expression levels of CD86 (B) and CD40 (C) are shown. Additional pDC data are
presented in Fig. S1a. (d) Proportions of lymph node CD69 positive cytotoxic NK cells (CD3–/CD56dim/CD16+) are shown. Additional NK cell data are presented in Fig. S1b.
(e) Proportions of activated (HLA-DR+/CD38+) lymph node effector memory (CCR7–/CD45RA–) CD4+ (left) and CD8+ (right) T cells are shown. Additional T cell data are presented
in Fig. S1c-e. (f) Volcano plot highlighting p-values and the MGN1703-induced fold changes fromweek 24 to baseline of genes related to Interferon [IFN (orange)] and Toll-like Receptor
[TLR (purple)] signalling. MGN1703 regulated transcriptswith an FDR b 5% is highlighted. Multiple comparisons accounted for as described in themethods. (g-h) Example baseline and on
treatment (week 24) immunohistochemistry stains for ISG15 protein are shown (g). This stain was performed prior to direct inspection quantitation of the numbers of ISG15 positive cell
profiles in the lymph node cortex reported in (h). Statistics:Wilcoxonmatched-pairs signed-rank test (b-e;h). Axis time notations: baseline (BL) and 24weeks (24). The n value for each
analysis is defined via individual participant data points, which are graphed with grey symbols/lines and defined in adjacent legends or individually labelled in correlation plots. Black
circles represent median points.
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tometry as described below or lysed and preserved at -80 °C in RLT+
buffer (Allprep isolation kit, Qiagen #80204, Germantown, MD) for
PCR to detect viral nucleic acids and RNASeq analyses. For some of the
lymph nodes therewas not sufficient amount of tissue to do all the anal-
yses and we had to prioritize which analyses were performed. Lymph
nodes that were analysed will be noted with labels in each Figure.
2.3. Flow cytometry
Flow cytometry analyses were performed on red blood cell (RBC)-
lysed peripheral blood leukocytes (15 min at room temperature in 1×
RBC lysis buffer, Biolegend, CA, USA) (baseline, week 12 and week 24)
or freshly isolated LNMC (baseline and week 24) (Fig. 1a). For all stains,
Fc-receptors were blockedwith Human Trustain FcX blocking buffer for
5 min at 4 °C (BioLegend, CA, USA). Cells weremixedwith antibodies in
BD Horizon™ Brilliant Stain Buffer (BD Biosciences, USA) and incubated
in the dark for 20 min at 4 °C, then washed twice in PBS+ 2% FBS). The
size of plasma blasts was estimated based on median forward scatter
values for the gated population. All sample data were acquired on a
FACSVerse (BD Biosciences, USA) and analyses were performed using
FlowJo software (v. 10·0·8r1) [Research Resource Identifier (RRID):
SCR_008520] (Treestar, Inc., OR, USA). List of antibodies is presented
in Table S1.
2.4. RNA sequencing
Cellular RNA was purified using the AllPrep DNA/RNA kit (Qiagen,
Ventura CA) as specified by the manufacturer. RNA quality was vali-
dated using the Agilent TapeStation, and the High Sensitivity RNA
Screentape (Agilent, Santa Clara, CA) and quantity was determined
using the Qubit 2·0 Fluorometer (ThermoFisher Scientific, Waltham,
MA). cDNA was generated from 10 ng of total RNA using the SMART-
Seq v4 Ultra Low Input RNA Kit for Sequencing (Takara Bio USA, Inc.,
Mountain View, CA) according to manufacturer's directions. Then,
150 pg of the cDNAwas used to prepare library for Illumina sequencing
using the Nextera XT Library Prep Kit (Illumina, San Diego, CA) accord-
ing to manufacturer's directions. Overall library size was determined
using the Agilent TapeStation and the DNA High Sensitivity 5000
Screentape (Agilent, Santa Clara, CA). Equimolar number of libraries
were pooled, denatured and High-Output, Single-Read, 36/38 base
pair paired end Next Generation Sequencing was done on a NextSeq
500 (Illumina, San Diego, CA).
2.5. RNASeq analysis
RNA-seq data was aligned using bowtie2 against hg38 version of the
human genome and RSEM v1.2.12 software was used to estimate raw
read counts and RPKM using Ensemble transcriptome information.
DESeq2was used to estimate significance of differential expression be-
tween two groups [23–25]. Genes with expression changes passing
FDR b 5% threshold changed at least two fold were considered signifi-
cant. Gene set enrichment analysis was done using QIAGEN's
Ingenuity® Pathway Analysis software (IPA®, QIAGEN Redwood City,
www.qiagen.com/ingenuity; RRID:SCR_008653) using “Canonical path-
ways” categories. Select pathways that passed p b .05 significance
threshold and had at least 5 significantly changed genes were reported.
The abundance of cell types was estimated using CIBERSORT software
(RRID:SCR_016955) [26]. The CIBERSORT analysis was performed on
RNAseq DESeq2-normalized read counts without quantile normaliza-
tion in relative and absolute modes. Significance of changes in cell
type abundance between treated and untreated patients was tested
using paired t-test and results with p b .05 were considered significant.
Correlation of RNAseq DESeq2-normalized read counts was done using
Pearson correlation and nominal p-values were adjusted for multiple
testing using Benjamini-Hochberg procedure [27].
2.6. Immunohistochemistry (IHC)
IHC was performed on formalin-fixed paraffin-embedded (FFPE)
4–5 μm serial sections as previously described [28]. Briefly, sections
were deparaffinized and rehydrated followed by heat-induced epitope
retrieval (HIER) performed with Citrate buffer pH 6·0 (Sigma-Aldrich)
or Citraconic Anhydride buffer (details are provided in Table S2. When
necessary, blocking was performed with 1% Casein in TBS
(ThermoFisher Scientific,) for 30 min at room temperature. Subse-
quently, the sections were incubated with optimized concentrations of
unconjugated primary antibodies diluted in blocking buffer (1% Casein)
for 1 h at room temperature or overnight at 4 °C. Thereafter, the sections
were washed and incubated with 3% H2O2 to block endogenous perox-
idases, followed by detection of primary antibody with an appropriate
Polink-1 or Polink-2 polymer detection kit (GBI Labs) conjugated with
Horseradish Peroxidase or Alkaline phosphatase. Between each step,
the sectionswere washed three timeswith 1× TBS-Tween20. To visual-
ize the sites of antigen expression, ImmPACT DAB (3,3′-diaminobenzi-
dine) Substrate (Vector Laboratories) or Warp Red ™ (Biocare
Medical) was added for 2 min at room temperature. Finally, sections
were counterstained with Hematoxylin, for Warp Red developed slides
covered with ClearMount (diluted 1:5 in ddH20; Invitrogen), dried for
60 min at 60 °C or overnight at 40 °C, and all slides were mounted
with Permount (Electron Microscopy Sciences) and scanned at high
magnification (x200) using the Aperio AT2 System (Leica Biosystems)
yielding high-resolution data from the entire tissue section. List of pri-
mary antibodies and conditions is provided in Table S2. The number of
ISG15 positive cells was quantified as previously described [6,29]. The
frequency of CD4 (DAB) positive cells was quantified using FIJI version
2·0·0-rc68/1·52i. After color deconvolution (FastRed, FastBlue, DAB)
the threshold for DAB was evaluated and set to 100.
2.7. Immunofluorescent (IF) assays
IF stains were performed to assess the impact of MGN1703 on B cell
follicle maturation. In total 56 sections of 5 μmeachwere assessed (i.e.7
participants × 2 time points x 4 sections per time pointwhere the 4 sec-
tions were serially cut with 25 μm distance between assayed sections).
Primary and secondary B cell follicles were visualized using anti-CD4,
anti-CD20, and anti-IgD antibodies. IF was performed on formalin-
fixed paraffin-embedded (FFPE) 5 μm serial sections. Sections were
deparaffinized and rehydrated followed by heat-induced epitope re-
trieval (HIER) performedwith Citraconic Anhydride (CA) buffer (details
are provided in Table S2). After HIER the tissue was left in the CA buffer
to cool at RT for 20 min followed by a 10 min wash in dH2O. Then they
werewashed in 0·1% TBS-Tween20 before incubatingwith anti-IgD at 4
°C overnight. Thereafter, the sections were washed and incubated with
1·5% H2O2 to block endogenous peroxidases. Then, sections were incu-
bated with a Polink-2 Rabbit polymer kit conjugated with Horseradish
Peroxidase (HRP) (GBI-labs). Between each step, the sections were
washed 10 min with 0·1% TBS-Tween20. To visualize the sites of anti-
gen expression Tyramide signal amplification (TSA) reagent conjugated
with Alexa Fluor™488 was added in a 1:500 dilution for 10 min. Before
incubating the slide with anti-CD20 antibody overnight at 4 °C the sec-
tions were microwaved at power level 10 for 1 min followed by 15min
at power level 2, cooled for 10 min, washed twice with dH2O and
washed once with 0·1% TBS-Tween20. Anti-CD20 antibody stain was
visualized using a Polink-2 Mouse polymer kit conjugated with Horse-
radish Peroxidase and TSA reagent conjugated with Alexa Fluor™647.
Finally, after a second round in the microwave as described above,
CD4 was detected by incubating primary anti-CD4 antibody for 1 h at
RT followed by secondary anti-Rabbit antibody conjugated with Alexa
Fluor™594 (RRID: AB_2534073). DNA was visualized with DAPI
(Invitrogen) 1:25,000 for 10min. To prevent autofluorescence, sections
were incubated with filtered Sudan Black (diluted 10:1 in 10xTBS) for
20 min, washed and mounted with Prolong Gold anti-fade mounting
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media. Sections were imaged using a Keyence BZ-X710 at 20× (Nikon
Plan Apo; NA 0·75) and stitched using Keyence software, and primary
and secondary follicles were manually counted. Primary B cell follicles
were defined if the germinal center was IgD positive, whereas second-
ary B cell follicles were IgD negative in the germinal center. All tissue
sections were analysed and subsequently top and bottom of secondary
follicle that initially was characterized as a primary follicle was
corrected and counted as a secondary follicle when detected as such
on another section.
2.8. Plasma IgG quantification
Total IgG as well as IgG1, IgG2, IgG3 and IgG4 plasma levels were
determined at the Clinical Biochemistry Lab at Aarhus University Hospi-
tal, Aarhus, Denmark.
2.9. Glycan analysis
Lymph node wash was concentrated using Amicon Ultra-4 Centrifu-
gal Filter Unit (Millipore Sigma). Total IgGwas purified fromplasma and
concentrated lymph node wash using Pierce™ Protein G Spin Plate for
IgG Screening (Thermo Fisher). IgGs from lymph node wash was con-
centrated using Amicon Ultra-0·5 Centrifugal Filter Unit (Millipore
Sigma). N-glycans were released using peptide-N-glycosidase F
(PNGase F) and labelled with 8-aminopyrene-1,3,6-trisulfonic acid
(APTS) using the GlycanAssure APTS Kit (Thermo Fisher), following
the manufacturer's protocol. Labelled N-glycans were analysed using
the 3500 Genetic Analyzer capillary electrophoresis system. Relative
abundance of IgG glycan structures was quantified by calculating the
area under the curve of each glycan structure divided by the total
glycans.
2.10. Antibody neutralization assay: protocols for neutralizing antibody
assay
Our protocols for production and titration of Env-pseudotyped vi-
ruses and neutralizing antibody assays are adapted from protocols
from David C. Montefiori lab: https://www.hiv.lanl.gov/content/nab-
reference-strains/html/home.htm [30].
2.11. Antibody neutralization assay: cell culture
HEK-293 T cells and TZM-bl cells (obtained though NIH AIDS Re-
agents Programme (Cat#8129) from Dr. John C. Kappes, and Dr.
Xiaoyun Wu [31–35];) were cultured in complete DMEM (cDMEM)
that is: DMEM (Gibco #11960–044) + 10% FCS + 2 mM L-Glutamine
(Thermo # 25030024) + 1 mM Sodium Pyruvate (Gibco#
11360–070) + 50 μg/mL Gentamicin (Sigma # G1397-10ML)
+ 20 mM HEPES (Biochrom # L1613).
2.12. Antibody neutralization assay: luciferase reporter gene assay
TZM-bl cells were incubated with the virus for 48 h. For develop-
ment a luciferin/lysing-agent (10 mM MgCl2 (Sigma #M8266)),
0.3 mM ATP (Sigma #A2383), 0.5 mM Coenzyme A (Sigma #C3144),
1 mM D-Luciferin (Zellbio # LUCNA), and 17 mM IGEPAL (Sigma#
I8896) in Tris-HCL was added to all wells. After 2 min the supernatant
was transferred to a new black 96-well plate (Corning #CLS3915) and
the relative light units (RLUs) were detected on a luminometer.
2.13. Antibody neutralization assay: production and titration of Env-
pseudotyped viruses
A Panel of twelve global HIV-1 Env clones was used that represents
the major genetic subtypes and circulating recombinant forms of HIV-
1 [36]. Twelve plasmids encoding envelopes and a backbone plasmid
(pSG3deltaENV NIH AIDS Reagents Programme #11051) were ex-
panded in STBL3 bacteria at 37 °C for 16 h and then purified using
MidiPrep kit (MachereyNagel). Control pseudovirus encoding envelope
from murine leukaemia virus (MLV) was expanded in the same way.
293 T cells were seeded on T75 flasks at such a density that after 24 h
of culture they reached 60–90% confluency. When cells reached
confluency, they were transfected with 4 μg of plasmid encoding enve-
lope and 8 μg of backbone plasmid using Fugene HD (Promega
Cat#E2311). After 3 h media was exchanged and the cells were incu-
bated for the next 24 or 48hwhen the supernatantswith pseudoviruses
were collected, filtered through 0.45 μm filter, aliquoted and stored at
-80 °C. Env-pseudotyped viruses were titrated by preparing serial dilu-
tions on 96-well plate in cDMEM. TZM-bl cells resuspended in cDMEM
containing 10 μg/mL DEAE dextran were seeded on a plate with
pseudoviruses dilutions and incubated for 48 h. We performed lucifer-
ase assay to calculate virus titer. Minimum level of infectivity had to
have the luminescence signal at least 10 times higher than the cell con-
trol wells but not high enough to cause cytotoxicity.
2.14. Antibody neutralization assay: readout
Plasma from the patients was inactivated at 56 °C for 45min. 0·5mL
of plasma was mixed with 14 mL of PBS and 250 μL of Protein G sepha-
rose 4 Fast Flow (GEHealthcare Cat#17–0618) and incubatedwith rota-
tion overnight at 4 °C. Samples were spun at 1250 rpm for 5 min,
supernatants were removed and protein G sepharose with bound IgG
was applied onto poly-prep chromatography column (Biorad
Cat#7311550). The column was washed three times with PBS. IgG
was eluted from the columnwith 2mLof 0·1Mglycine pH 3 (AlfaAesar,
Cat#J62527). Solution was neutralized with Tris pH 8·0. Buffer was ex-
changed to PBS on Amicon ultra-4 centrifugal unit ultracel 30
(SigmaAldrich Cat# Z740192). IgG concentration was measured on
Nanodrop Denovix DS11FX. Serial dilutions of IgG from each patient
were incubated with appropriate dilution of Env-pseudoviruses on 96-
well plates for 60 min. After 60 min TZM-bl cells in cDMEM with 10
μg/mL of DEAE dextran were seeded on the plates with IgG and Env-
pseudoviruses. 48 h later we performed luciferase assay and calculated
antibody neutralization as IC50 (μg/mL).
2.15. Cell-associated HIV-1 DNA and unspliced HIV-1 RNA
We used digital droplet PCR (ddPCR) to quantify HIV-1 nucleic acid
levels in LNMC. Template preparation and denaturation were per-
formed as previously described [37]. Primers and probes are listed in
Table S3. Samples were assayed in triplicates for HIV-1 DNA and dupli-
cate for theRPP30 reference gene. UnsplicedHIV-1 RNAwere assayed in
six replicates, whereas the reference genes TBP and IPO8 were assayed
in duplicates. Droplet generation was done according to manufacturer's
instructions using a QX100 droplet generator. The PCR reactionwas car-
ried out on a Bio-Rad CFX96 Thermal Cycler. Reading of droplets was by
the QX100 droplet reader (Bio-Rad, USA). Data were analysed using
QuantaSoftTM software (Bio-Rad, USA).
2.16. RNAScope/immunofluorescence (IF) multiplex
RNAScope/IFmultiplex assays were performed to quantify the num-
ber of follicular dendritic cell-associated virions and HIV RNA positive
cells. RNAScope/IF multiplex was performed on formalin-fixed
paraffin-embedded (FFPE) 5 μm serial in essence as previously de-
scribed [38] with some modifications. Sections were deparaffinized
and rehydrated RNAScope/IF multiplex HIER was performed in boiling
ACD target retrieval buffer for 15 min. Sections were deparaffinized
and rehydrated and HIER was performed in boiling ACD target retrieval
buffer for 15 min. Sections were treated with ACD Protease III (1:10 di-
lution in PBS) for 20 min at 40 °C, followed by ACD H2O2 treatment for
10 min at RT. Between steps, the sections were rinsed twice in dH2O.
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Target probes (HIV-1 Clade B # 41611, For ID117 HIV Clade C #429841,
ACD) were incubated at 40 °C for 2 h and the signal was amplified ac-
cording to ACD RNAScope2·5 HD BROWN kit protocol, with the excep-
tion that we utilized 0·5× wash buffer for all washing steps.
Development of amplified RNA was performed with Tyramide signal
amplification (TSA) reagent conjugated with Alexa Fluor™488 added
in a 1:500 dilution for 10min. Before incubating the anti-CD20 antibody
overnight at 4 °C the sections were microwaved at power level 10 for
1 min followed by 15 min at power level 2, cooled for 10 min, washed
twice with dH2O and washed once with 0·1% TBS-Tween20. Anti-
CD20 antibody stain was visualized using a Polink-2 Mouse polymer
kit conjugated with Horseradish Peroxidase (GBI-labs) and TSA reagent
conjugated with Alexa Fluor™594. Finally, CD35 was detected by incu-
bating primary anti-CD35 antibody overnight at 4 °C followed by sec-
ondary anti-rabbit antibody conjugated with Alexa Fluor™647. DNA
was visualized with DAPI (Invitrogen) 1:25,000 for 10 min. To prevent
autofluorescence, sections were incubated with filtered Sudan Black
(diluted 10:1 in 10xTBS) for 20min,washed andmountedwith Prolong
Gold anti-fade mounting media. Sections were imaged and stitched
using a Keyence BZ-X710 at 40× (Nikon Plan Apo; NA 0·60) and
stitched using Keyence software.
2.17. Biostatistical analyses
Two-tailed Wilcoxon signed-rank tests were utilized to analyse
changes from baseline, Spearman rank tests were used when detect-
ing data correlations. The statistical comparisons and graphs were
generated using GraphPad 7 and no outliers were censored. These
are biological observations from the same lymph node materials.
Therefore, the alpha was set to 0.05 without adjustments for the
121 statistical tests performed herein (97 Wilcoxon signed-rank
tests +24 Spearman rank tests – excluding RNA sequencing analy-
ses), according to the recommendation by Rothman [39]. Corrections
for multiple comparisons were made during analyses of the RNA se-
quencing dataset as described above. Interpretations of the Spear-
man rank outcomes are based upon the approach published by
Hinkle, Wiersma, & Jurs [40]. For r values between 0.90 and 1.00
(−0.90 and− 1.00), the interpretation was: very high positive (neg-
ative) correlation. For r values between 0.70 and 0.90 (−0.70 and−
0.90), the interpretation was: high positive (negative) correlation.
For r values between 0.50 and 0.70 (−0.50 and− 0.70), the interpre-
tation was: moderate positive (negative) correlation.
3. Results
3.1. Lymph nodes exhibited a potent interferon response following
MGN1703 therapy
This was a predefined sub-study, which investigated the impact of
24 weeks MGN1703 treatment on lymph node biology. We included
HIV-1 infected participants from a phase 1b/2a clinical study wherein
they received MGN1703 (s.c., 60 mg 2× weekly for 24 weeks) concur-
rent with combination antiretroviral therapy (cART). The primary pur-
pose of the trial was to pursue a potential role for TLR9 agonism in the
context of HIV cure research and primary study outcomes have been re-
ported previously [8]. Eight study participants (Table S4) volunteered
for participation in the lymph node sub-study. Of these, seven partici-
pants completed the sub-study and provided inguinal lymph nodes
for analyses at both baseline and during the last week of dosing
(Week 24; Fig. 1a). Adverse events related to lymph node excisions
were graded in accordance with the Common Terminology Criteria for
Adverse Events (CTCAE) version 4.0 (Table S5).
Hallmarks of TLR9-agonist treatment are activation of pDCs, NK cells
and T cells [6–8,41,42]. Therefore, we examined lymph node and pe-
ripheral blood mononuclear cells (LNMCs and PBMCs, respectively) of
study participants at baseline and at 24weeks of treatment for evidence
of MGN1703-mediated immune cell activation. With respect to LNMC,
we detected elevated expression (p=0·063) of the activation markers
CD86 and CD40 on pDCs (Figs. 1b-c and S1a) and a significant increase
(p = 0·031) in the proportion of CD69-expressing LNMC NK cells dur-
ing MGN1703 dosing (Figs. 1d and S1b). Within the lymph node T cell
compartment, the greatest impact of MGN1703 dosing was observed
in the context of the activation status of CD8+ T effector memory cells
(HLA-DR+/CD38+; p = 0·016) (Figs. 1e and S1c-e). These LNMCs
data are consistent with PBMC data from this study cohort [8].
Another hallmark of TLR9-agonist stimulation is activation of in-
terferon response pathways [4,41]. To examine whether these and
related pathways were affected in lymph nodes after 24 weeks of
MGN1703 therapy, we performed longitudinal global transcriptomic
analyses using RNASeq on LNMC from baseline and 24 weeks post
therapy. The volcano plot in Fig. 1f and the Ingenuity Pathway Anal-
yses in Table S6 illustrate the robust activation of gene expression re-
lated to both interferon as well as TLR signalling that we observed.
Among the transcriptomic changes highlighted in Fig. 1f is the in-
creased expression of interferon stimulated gene 15 (ISG15) in
LNMC following MGN1703 treatment. Protein level confirmation of
the RNASeq findings was demonstrated by quantitative immunohis-
tochemistry on sections of lymph node tissues from this study co-
hort. Here, we found that ISG15 expression increased significantly
in the lymph node cortex (Fig. 1g-h). Overall, the flow cytometry
and RNASeq data together with the quantitative IHC findings reveal
that 24 weeks of MGN1703 dosing resulted in a robust interferon re-
sponse in the lymph nodes of the treated individuals.
3.2. MGN1703 induced B cell differentiation
B cell differentiation is a multi-stage process whereby B cells at dis-
tinct stages can be distinguished by their cell surface phenotype
[43–45]. In the lymph node, B cell differentiation stages include transi-
tional, naïve/mature, marginal zone, follicular, germinal center,
switched memory and plasma blasts (gating strategy in Fig. S2a) [45].
These populations, with the exception of germinal center B cells, can
also be found in peripheral blood (gating strategy in Fig. S2b) [44]. We
examined LNMC (baseline and week 24) and PBMC (baseline, week
12 and week 24) by flow cytometry and found that MGN1703 dosing
promotes B cell differentiation evidenced by increases in LNMC follicu-
lar and germinal center B cells as well as increases in both the propor-
tion of LNMC and PBMC plasma blasts (Figs. 2a and S2c). Furthermore,
when analysing the changes in the median size of LMNC and PBMC
plasma blasts we found a significant increase in LMNC plasma blasts
(p = 0·047), whereas PBMC plasma blast size were decreased after
12 weeks (p = 0·034) and unchanged after 24 weeks (p = 0·30).
Also, we noted that there was an association between LNMC B cell mat-
uration from germinal center B cells to plasma blasts (p b 0·0001;
Fig. S2d). In addition, we analysed the levels of lymph node CD21low/
CD38low activated B cells, as well as immature B cells; both were un-
changed with treatment. These flow cytometry data are consistent
with RNASeq data obtained from LNMCs and analysed according to
the CIBERSORT algorithm [26]. Specifically, the algorithm identified a
gene expression profile consistent with significantly more plasma cells
in the LNMC pool following MGN1703 dosing (Fig. 2b). Knowing that
MGN1703 dosing was inducing B cells to differentiate towards plasma
cells led us to examine the lymph node architecture for the presence
of primary and secondary follicles. When we examined the lymph
nodes at baseline versus 24 weeks post treatment, we found that the
number of primary follicleswas trending downwardswhile the number
of secondary follicles was trending upwards (Fig. 2c-d). These data may
indicate that TLR9 agonism contributes to the restoration of lymph node
architecture and function. Taken together, these data reveal that B cell
differentiation, maturation and functional potential are augmented in
the presence of MGN1703 in vivo.
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3.3. MGN1703 increased proportions of lymph node T follicular helper (Tfh)
cells
The changes in the B cell compartment that we observed following
MGN1703 dosing led us to also examine the T cell compartment with
a focus on Tfh cells. The primary function of Tfh cells is to provide
“help” in the positive selection of high affinity B cells as the B cells expe-
rience antigenic stimulation towards proliferation and differentiation
into plasma cells [12]. Using quantitative immunohistochemistry, we
showed that the ratio of CD4+ T cell found within B cell follicles versus
CD4+ T cells in the T cell zones of the lymph node tended to increase in
all participants analysed (p = 0·063; Fig. 3a-b). This finding was
consistent with our flow cytometry observation as well as our
RNASeq/CIBERSORT findings that revealed higher proportions of Tfh
cells within the total lymph node mononuclear cell compartment with
MGN1703 treatment (Fig. 3c-d). These changes in lymph node Tfh
levels were not associated with changes of this cell type in peripheral
blood as seen in Fig. S3. However, we found that an increase in PBMC
Tfh cells was moderately negatively correlated with an increase in
PBMC plasma blasts (p = 0·049; r=−0.59) indicating that the matu-
ration of B cells into plasma blasts may be T cell dependent (Fig. S3).
Comparing the changes in lymph node Tfh cells with plasma blasts
(p = 0·058; Fig. 3e) and lymph node Tfh cells with germinal center B
cells (p = 0·058; r= 0·8286) we observed an analogous outcome. In
Fig. 2.MGN1703 induces peripheral blood and lymph node B cell differentiation. (a) The proportions of lymphnodeB cell lineageswere impacted byMGN1703 treatment. Flow cytometry
gating for B cell lineages aswell as additional PB B cell lineage results are presented in Fig. S2. (b) Plot shows the abundance of lymphnode plasma cells predicted by CIBERSORT [26]. (c-d)
Representative images of immunofluorescentmultiplex lymphnode analyses (c) and quantitation of primary (large arrows) and secondary (small arrows) B cell follicles (d). DAPI: nuclei,
CD4: CD4+T cells, CD20: B cells, and IgD: naïve B cells. B cell follicleswere defined as secondarywhen IgDwas excluded fromgerminal centers. Statistics:Wilcoxonmatched-pairs signed-
rank test (a-b, d). Axis timenotations: baseline (BL) and 24weeks (24). Then value for each analysis is defined via individual participant data points,which are graphedwith grey symbols/
lines and defined in adjacent legends or individually labelled in correlation plots. Black circles represent median points.
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summary,MGN1703dosing led to increased proportions of Tfh cells and
this effect was particularly notable in lymph node, which is the anatom-
ical location for Tfh function.
3.4. MGN1703 increased IgG production and AID expression
When we quantitated plasma levels of total IgG as well as IgG sub-
classes, we observed significantly elevated levels of total IgG, IgG1,
IgG2, and IgG3 at week 12 of treatment versus baseline (Fig. 4a). In
line with the results shown in Fig. 3e and Fig. S3c we also observed a
very high correlation between the increase in total plasma IgG at
week 12 and the increase in LNMC Tfh cells at week 24 (p = 0·017,
r = 0.94; Fig. 4b) supporting the idea that TLR9 agonist enhancement
of B cells involves T cell help. The observed changes in IgG subtypes
and the fact that B cell differentiation typically is associated with anti-
body class switching and affinity maturation [46] led us to look into
the expression of the activation-induced cytidine deaminase (AID)
gene, a key regulator of B cell diversification and somatic
hypermutation. LNMC RNASeq analyses at week 24 showed a 5·65-
fold increase in expression compared to baseline (Fig. 4c) indicating
that the potential for somatic hypermutation is induced by MGN1703
treatment.
We previously showed that MGN1703 might induce latent HIV ex-
pression in some individuals [7]. Therefore, we hypothesized that de-
spite ongoing cART during MGN1703 dosing; there could be low-level
expression of HIV antigens towards which the elevated antibody re-
sponse could be directed. We tested both aspects of this hypothesis in-
cluding changes in viral RNA levels as well as antibody neutralization
capacity. Regarding viral nucleic acids: Among the seven individuals in-
cluded in this study, we did not observe cohort-wide changes in LNMC-
associated HIV DNA or RNA levels (Fig. S4a-b). Furthermore, when we
performed fluorescence in situ hybridization assays (i.e. RNAScope) on
sections of lymph node tissue to detect follicular dendritic cell-bound
virions and viral RNA positive cells, we found a paucity of HIV RNA
within lymph nodes (Fig. S5). Specifically, no follicular dendritic cell-
associated virions were observed within the 34·6mm2 of B cell follicles
that were analysed. This area of B cell follicles inspected is the aggregate
area from the total of fifty-six 5 μm sections assessed. In 17·2 mm2 of T
cell zones that were visually inspected, we only found four HIV RNA
positive cells. Thus, we did not find evidence of MGN1703-induced la-
tency reactivation in lymph nodes at week 24. Regarding antibody neu-
tralization capacity: We found that the MGN1703-mediated
upregulation of six immunoglobulin light chain genes and one Ig
heavy chain variable gene were associated with MGN1703-induced re-
duction of HIV DNA levels in LNMCs (Fig. S4c). These data combined
with our finding that changes in plasma IgG levels were highest at
week 12 (Fig. 4a), led us to assess plasma antibodies' anti-HIV capacity
using a standard HIV neutralization assay developed for identifying
broadly HIV neutralizing antibodies [36]. As the majority of Danish
HIV-infected individuals are infected with subtype B virus, we stratified
Fig. 3.MGN1703-induced B cell differentiation is associated with increased proportions of T follicular helper cells in peripheral blood and lymph nodes. (a) Example baseline and on
treatment (week 24) immunohistochemistry stains for CD4 are shown. This stain was performed prior to quantitation of the frequency of CD4+ T cell profiles in B cell follicles (BCF)
and T cell zones (TZC). Co-staining with the myeloid markers CD68 and CD163 was incorporated to facilitate differentiation between CD4+ T cells and CD4+macrophages. (b) The
frequency of CD4+ T cells in BCFs and TCZs was quantified and the ratios of CD4+ T cells in the BCFs and TZC are presented. (c) Proportions of lymph node Tfh cells (CD3 + CD4 +
CD45RA–CXCR5 + PD–1+) within the total lymph node mononuclear cell compartment are presented. Flow cytometry gating for Tfh cells is presented in Fig. S3a. Proportions of
peripheral blood Tfh cells are presented in Fig. S3b (d) Plot shows the abundance of lymph node Tfh cells estimated using CIBERSORT [26]. (e) Plot shows a positive association
between changes in proportions of plasma blasts and Tfh cells in lymph nodes. Plot showing a positive association between changes in proportions of plasma blasts and Tfh cells in
peripheral blood is presented in Fig. S3c. Statistics: Wilcoxon matched-pairs signed-rank test (b-d) or Spearman rank test (e). Axis time notations: baseline (BL) and 24 weeks (24).
The n value for each analysis is defined via individual participant data points, which are graphed with grey symbols/lines and defined in adjacent legends or individually labelled in
correlation plots. Black circles represent median points.
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the neutralizing capacity data into B and BC clades or A and AE clades.
We identified a trend towards an elevated (p=0·054) clade B/BC neu-
tralizing capacity at week 12 when the increased total levels of IgG in
plasma were also observed (Fig. 4d), whereas there was no change in
the ability of the patient IgG to neutralize clade A and AE envelopes
(Fig. 4e). Together these data indicate thatMGN1703 dosing induced in-
creases in plasma IgG secretion with potential affinity maturation of
these antibodies towards HIV clade B/BC specificity.
3.5. MGN1703 modulated antibody glycosylation patterns
We examined the glycosylation patterns on peripheral blood- as
well as lymph node-derived antibodies. We observed that multiple
major glycosylation patterns (e.g. sialylated and galactosylated) were
modulated by TLR9 agonist treatment in both compartments (Figs. 5a
and S6). The glycosylation changes on plasma antibodieswere observed
at both week 12 and week 24. We next examined whether the changes
in plasma antibody glycosylation patternswere associatedwith changes
in the size of the HIV reservoir. We identified strong associations be-
tween specific glycosylation patterns and reductions in the HIV reser-
voir measurements (Fig. 5b-d). We noted that decreases in grouped
mono-galactosylated plasma antibodies were highly negatively corre-
lated with increased levels of HIV RNA in circulating CD4+ T cells
(p = 0·018, r = −0.77; Fig. 5b). We also observed that increases in
grouped sialylated plasma antibodies were highly negatively correlated
with reduced levels of HIV DNA in CD4+T cells (p=0·018, r=−0.71;
Fig. 5c). Similarly, we found that increases in levels of A2G2S1 glycan
motif on plasma antibodies were moderately negatively correlated
with reduced levels of HIV DNA in circulating CD4+ T cells (p =
0·031, r = −0.66; Fig. 5d). In conclusion, we found that MGN1703
significantly altered antibody glycosylation patterns and key glycosyla-
tion changes can be linked with reduction in HIV reservoirs.
4. Discussion
In this study, we longitudinally analysed the impact of MGN1703 on
mononuclear cells within inguinal lymph nodes and peripheral blood of
HIV infected individuals. We found that MGN1703 activated pDCs, NK
cells, and T cell as well as induced a robust interferon response in
lymph nodes. Furthermore, we found that MGN1703 dosing increased
B cell differentiation and secondary B cell follicle formation. Changes
in B cell population dynamics were accompanied by increased IgG pro-
duction and changes in antibody glycosylation patterns. The latter was
associated with reductions in the levels of HIV persisting within the
lymph nodes during cART.
In the current study, we examined inguinal lymph nodes, as repre-
sentative secondary lymphoid tissues, for evidence of tissue penetration
and sustained activity of MGN1703 in these anatomical sites. We did
this because data detailing the effects of in vivo TLR9 agonism within
human tissues are very limited. Lymph node effects of TLR9 agonism ex-
ists in the context of cross-sectional studies, which probed the effects of
CPG ODNs on dendritic cells present in sentinel lymph nodes from early
stage melanoma patients [47–49]. Beyond lymph nodes, we have pub-
lished a longitudinal study showing that MGN1703 induced a type I,
but not a type II, interferon response in a mucosal site – namely the sig-
moid colon of HIV infected persons [6]. In contrast to many of our mu-
cosal tissue findings [6], the activation of T cells that we observed here
in the lymph nodes was similar to our peripheral blood findings at the
same time points [8]. We also observed similar levels of NK cell and
pDC activation when comparing lymph node and peripheral blood re-
sults. Thus, TLR9 agonism-induced outcomes in blood and lymph node
resemble each other more so than blood and sigmoid colon outcomes.
There aremajor distinctions in the physiological roles ofmucosal tissues
versus secondary lymphoid tissues that likely explain the differences
observed. Specifically, the lymphnodes are anatomical sites for the gen-
eration of adaptive immune responses whereas the immune responses
Fig. 4.MGN1703 induces plasma IgG secretion that specifically neutralizeHIV clade B andC. (a) Plasma IgG and IgG subtype levels are shown. (b) Plot shows a positive association between
the changes in plasma IgG and the changes in lymph node Tfh cells. (c) Graph shows the fold change of Activation-Induced cytidine Deaminase (AID) expression from baseline to on
MGN1703 treatment at 24 weeks (d-e) Neutralization outcomes against Clade B and B/C (d) and Clade A and AE (e) envelopes are depicted. MPI = maximum percent inhibition.
Statistics: Wilcoxon matched-pairs signed-rank tests for on treatment timepoints vs. baseline (a; d-e) or Spearman rank test (b). Axis time notations: baseline (BL), 8 weeks (8),
12 weeks (12), and 24 weeks (24). The n value for each analysis is defined via individual participant data points, which are graphed with grey symbols/lines and defined in adjacent
legends or individually labelled in correlation plots. Black circles represent median points.
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in the intestines are tightly regulated to prevent hyper-inflammation di-
rected towards the constantly present stimulatory milieu at this ana-
tomical site.
We present evidence of TLR9 agonist induced effects on B cell differ-
entiation, maturation and function in both peripheral blood and lymph
nodes. Consistent with follicular B cells aggregating in lymph nodes and
differentiating into germinal center B cells [12], we observed increases
in follicular B cell population in lymph nodes simultaneous to this pop-
ulation becoming proportionally smaller in the peripheral blood. Fur-
thermore, this change in lymph node follicular B cells occurred as the
germinal center B cell population, which increased in 5 of 7 lymph
node pairs evaluated. Moreover, we observed architectural differences
during MGN1703 treatment with respect to increased numbers of sec-
ondary B cell follicles – the primary anatomical location for antibody af-
finity maturation. The changes in B cell populations and lymph node
architecture were accompanied by increases in plasma IgG levels at
week 12. As these changes are subtle, the biological relevance of the
changes is not proven here. However, it is important to note that
these data align linewith previous data showing increase in IgG produc-
tion following ex vivo MGN1703-stimulation of PBMCs [50]. The
12 week time point is in accordance with the time point where we ob-
served a modest increase in HIV neutralization capacity by plasma anti-
bodies. While it is well established that B cell population abnormalities
and dysfunctions result from HIV infection [51–54], our LNMC RNASeq
data showed a 5·65-fold increase in expression of activation-induced
cytidine deaminase (AID) at week 24. AID enzymatic activity is critical
for both antibody class switching as well as somatic hypermutation
leading to antibody affinity maturation [55]. Thus, our data suggests
that MGN1703 treatment changes B cell differentiation in HIV-
infected individuals. Since these changeswere associatedwith increases
in Tfh cell proportions and increased AID expression, it is likely that the
changes in antibody production were T-dependent in nature.
Beyond their well described fundamental roles in initiating and
maintaining adaptive immune responses, lymph nodes are of particular
interest in HIV infection. First, lymph node architecture of distinctly de-
fined B cell follicles and T cells zones is disrupted during untreated in-
fection by fibrosis and this damage is not fully reversed by long-term
standard-of-care treatment (cART) [56–59]. Thus, the observed trends
towards secondary B cell follicle formation suggest that repeated TLR9
agonism can further reverse HIV-induced lymph node damage that ac-
cumulates prior to cART administration. A second reason that lymph
nodes are of particular interest in HIV infected persons, is that lymph
nodes harbor persistent HIV reservoirs during cART and these viral res-
ervoirs represent the greatest barrier to a cure for HIV [60–63]. Despite
the recognized importance of lymph nodes in HIV disease, there is lim-
ited longitudinal lymph node data to provide insights into the stability
Fig. 5.MGN1703 changes plasma antibody glycosylation patterns. (a) Immunoglobulin glycosylation profiles were assessed in plasma. Immunoglobulin glycosylation profiles assessed in
lymph node wash are shown in Fig. S5. (b-d) Plots show negative associations between key plasma antibody glycosylation parameters and changes in PB CD4+ T cell-associated HIV-1
RNA/DNA. Total lymph nodemononuclear cell-associated HIV-1 RNA/DNA is presented in Fig. S4a-b. Statistics:Wilcoxonmatched-pairs signed-rank tests for on treatment timepoints vs.
baseline (a) or Spearman rank test (20 total performed) (b-d). Axis time notations: baseline (BL), 8 weeks (8), and 24 weeks (24). The n value for each analysis is defined via individual
participant data points, which are graphed with grey symbols/lines and defined in adjacent legends or individually labelled in correlation plots. Black circles represent median points.
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of thepersistentHIV reservoir in lymphnodes during cART [64]. Recently
published data from some of these same lymph nodes show that the la-
tent viruses found in circulation overlap genetically with those found in
lymph nodes and that the overall frequency of HIV-1 proviruses in blood
and lymph node CD4+ T cells was the same [65]. Our current study of
these lymph nodes provides much needed insight into the longitudinal
stability of the HIV reservoir in lymph nodes, which is of paramount im-
portance in the realization of an HIV cure. One of themechanisms of HIV
persistence in lymph nodes is via virions being trapped and retained on
follicular dendritic cells as we and others have shown in HIV as well as
SIV infection [38,60,64,66,67]. Here, we could not identify follicular den-
dritic cell-associated virions in any lymph node sample analysed – in-
cluding baseline samples. As was true for locating follicular dendritic
cell-associated virions, we found HIV RNA producing cells to be exceed-
ingly rare in the lymph nodes of our study population, even at baseline.
Our observations of rare HIV RNA-associated cells in lymph nodes
could be explained, at least in part, by the fact that participants in this
lymph node study had been taking cART for a median of 6.3 years
which is well beyond the 30 months of triple antiretroviral therapy pre-
viously estimated to be required for elimination of viral RNA in second-
ary lymphoid tissues, specifically tonsils [68].
Glycans are highly diverse and complex carbohydrate structures
composed of branched monosaccharide chains [69]. Glycans are added
to many biological molecules (including proteins and lipids) via glyco-
sylation. We detected an increase in plasma IgGs after 12 weeks and
these plasma antibodies, as well as lymph node-derived antibodies, ex-
hibited MGN1703-dosing associated changes in glycosylation. Previous
publications showed that even subtle glycan modulations can lead to
significant differences in antibody activities, and that minor glycan spe-
cies can play a significant role in antibody effector function [70,71]. In-
terestingly, the significant changes in glycosylation on peripheral
blood antibodies were generally in the opposite direction from the
changes observed in lymph nodes. For example, the increases in
grouped di-sialylated motifs on plasma antibodies at week 24
contrasted with the downward trend for this parameter observed on
lymph node antibodies. These differences could reflect anatomical se-
questration of antibodies with specific glycosylation patterns based
upon a given antibody's likely effector function [e.g. antibody depen-
dent cellular cytotoxicity (ADCC), antibody dependent cellular phago-
cytosis (ADCP), and antibody dependent complement deposition
(ADCD)] [72–76]. When we focused our association analyses in the pe-
ripheral blood, we found that increases in plasma antibodies bound to
glycan motifs that included galactose and sialic acid molecules were
negatively correlated with reductions in PBMC-associated HIV DNA
and RNA levels. This is consistent with our prior work documenting
that higher levels of multiple glycosylation motifs, particularly those
that non-fucosylated galactosylated, are associated with lower levels
of cell-associated HIV DNA and RNA in vivo [77]. Our current data
linking glycosylation with changes in HIV reservoir measurements
highlight the potential beneficial effects of MGN1703-mediated modu-
lation of antibody glycosylation patterns. These data also substantiate
previous work showing the importance of these glycosylation motifs
in clearing persistent HIV, potentially via non-neutralizing Fc-
mediated effector functions of antibodies.
5. Conclusions
In this study, we present 24-week longitudinal analyses of human
lymph node immunology and HIV virology as we determined the im-
pact of TLR9 agonism in these important secondary lymphoid tissues.
We found that the impact of TLR9 agonism on lymph node lymphocyte
activation and B cell differentiation closely resembled outcomes in pe-
ripheral blood at match time points. We also report changes in B cell
population dynamics, increase in plasma IgG levels, increase in AID,
and changes in antibody glycosylation, which is known to have func-
tional implications. Finally,we show that specific antibody glycosylation
patterns associated with reductions in HIV reservoir levels. TLR9
agonism is a component of multiple planned and ongoing HIV cure re-
lated clinical interventions (e.g. NCT03837756). In this context, these
lymph node data are of exceptional value for future HIV cure related
clinical trials to guide their planning and interpretation. The lymph
node data provided here will also be of immediate value in the context
of oncological indications where they will contribute to the interpreta-
tion of incoming phase 3 trial data and the planning of future studies.
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